
|Videos|May 1, 2020
Dr. O'Regan on Breast Cancer Treatment Considerations During the COVID-19 Crisis
Author(s)OncLive Staff
Ruth O’Regan, MD, provides insight on how the COVID-19 crisis is impacting the care of patients with breast cancer.
Advertisement
Ruth O’Regan, MD, provides insight on how the COVID-19 crisis is impacting the care of patients with breast cancer. She also shed light on cardiac toxicities associated with HER2-directed therapy and what those events might mean with regard to treatment decisions in light of the pandemic.
Please visit
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5




































